Key result
Paclitaxel elicits a transient response in the first known case of congenital angiosarcoma.
Paclitaxel may have a role in the management of unresectable congenital angiosarcoma, as demonstrated by a transient response in this first reported case.
May support paclitaxel evaluation in unresectable congenital angiosarcoma; hypothesis-generating from single case, needing prospective validation.
Angiosarcoma is a rare diagnosis with a poor prognosis. We report the first known case of congenital angiosarcoma. We also report a transient response with paclitaxel, an agent that may have a role in unresectable angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Good et al. (2008) studied this question. Paclitaxel elicited a transient response in the first known case of congenital angiosarcoma, suggesting a potential therapeutic role for this agent in unresectable disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: